Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Focal MR-Guided Focused Ultrasound Treatment of Localized Low and Intermediate Risk Prostate Cancer

Clinical Trial Details

There are different treatment options for the treatment of prostate lesions. These options may include treatment by radiation therapy, cryotherapy, surgery, and thermal therapy. The intent of these therapies is to cure the prostate lesion while at the same time minimizing side effects such as erectile dysfunction and urinary incontinence. 

This study involves use of the ExAblate device for focal treatment of prostate lesion(s). Unlike surgery or radiotherapy which affects a large portion of the prostate or the entire organ, localized, or focal, therapy is intended to treat a small volume of tissue in which the lesion has been found by biopsy. Some surgery and radiotherapy techniques have been associated with side effects which most commonly include incontinence (not able to control bladder or bowel actions) and erectile dysfunction (not able to have or maintain an erection of the penis). Focal therapy provides an opportunity to treat small, pre-planned, localized areas of the prostate and may be able to destroy your lesion with fewer side effects. There are several focal therapies available for the treatment of localized prostate lesion, but all of them are invasive. 

ExAblate treatment works by focusing ultrasound to heat a small area of tissue; much like a magnifying glass can be used to focus light on a small spot of a surface. Unlike light, ultrasound passes through the skin into the body (without an incision) to a spot your doctor wants to destroy.

This study is investigating a non-invasive form of focal therapy for prostate lesions that is not yet approved by the FDA and is therefore not commercially available outside of clinical trials such as this one.

If you are interested in participating in enrollment for this clinical trial and are located in the Los Angeles, CA area, San Francisco, CA area or Fort Lauderdale – Miami, FL area, please visit this link to register:

Key Eligibility: 

Diagnosis of prostate cancer (adenocarcimona)

Detailed eligibility will be reviewed with the study team

Study contact by location

Upper East Side - Manhattan

Contact(s)

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1505016169

Status

Open to Enrollment

Age Group

Adult

Sponsor

Disease